ACE and retinal disorder: The EUCLID Study enrolled the diabetic patients observed that the angiotensin converting enzyme (ACE) inhibitor lisinopril reduced the risk of progression of retinopathy by approximately 50%, and also significantly reduced the risk of progression to proliferative retinopathy [6].